Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 75

Sort by

Sort Order Select

Journal Articles

Effect of isatuximab use in combination with autologous stem cell transplant on mobilized stem cell product and post-transplant immune recovery - Results of a randomized prospective Phase 2 trial

Divaya Bhutani, Shami Chakrabarti, Rajshekhar Chakraborty, Michael Hughes, Suzanne Lentzsch, Markus Mapara, Abhinav Deol, Joseph Uberti, Ran Reshef

Blood (2025) 146 (Supplement 1): 4062.

https://doi.org/10.1182/blood-2025-4062

Published: 2025

Journal Articles

Systematic review of non-icans neurological toxicities associated with BCMA and GPRC5D-directed CAR-T cell therapy in plasma cell dyscrasia

Manpreet Saini, Fnu Deeksha, Aditya Jandial, Sudhir Kumar, Arihant Jain, Gaurav Prakash, Alka Khadwal, Rajshekhar Chakraborty, Pankaj Malhotra, Charanpreet Singh

Blood (2025) 146 (Supplement 1): 2802.

https://doi.org/10.1182/blood-2025-2802

Published: 2025

Journal Articles

Deciphering the IKZF1 and MAP4K2 protein interactome in RASMut multiple myeloma reveals a novel regulatory pathway of IKZF1

Josefine Krüger, Shirong Li, Guifen Liu, Yuen Lam Dora Ng, Michael Hughes, Rajshekhar Chakraborty, Divaya Bhutani, Jan Krönke, Suzanne Lentzsch, Jing Fu

Blood (2025) 146 (Supplement 1): 2150.

https://doi.org/10.1182/blood-2025-2150

Published: 2025

Journal Articles

Interim analysis of LimiTec, a prospective trial of limited-duration teclistamab for relapsed/refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 5814.

https://doi.org/10.1182/blood-2025-5814

Published: 2025

Journal Articles

Isatuximab for the treatment of monoclonal gammopathy of renal significance (MGRS): Results from a prospective multicenter Phase 2 trial

Divaya Bhutani, Rajshekhar Chakraborty, Michael Hughes, Suzanne Lentzsch, Samuel Pan, Shayan Shirazayan, Sherley Mejia, Naomi Sender, Elizabeth Shelton, Meghan Sise

Blood (2025) 146 (Supplement 1): 579.

https://doi.org/10.1182/blood-2025-579

Published: 2025

Journal Articles

A machine learning model to predict risk of infection in patients receiving bispecific antibody therapy for multiple myeloma

Nicholas Semenkovich, Anand George, Aishee Bag, Mansi Shah, Sabarinath Radhakrishnan, Binod Dhakal, Samer Al Hadidi, Rajshekhar Chakraborty, Carolina Schinke, Anita D'Souza, Aniko Szabo, Meera Mohan

Blood (2025) 146 (Supplement 1): 2226.

https://doi.org/10.1182/blood-2025-2226

Published: 2025

Journal Articles

Quality and timing of patient-reported outcome reports in randomized controlled trials (RCTs) of patients with lymphoid malignancies: Analysis of 83 RCTs published between 2015 and 2025

Fabio Efficace, David Cella, Neil Aaronson, Gary S. Collins, Francesco Sparano, Rajshekhar Chakraborty, Darshi Shah, Veer Shah, Chiara Pallisco, Giorgia Novero, Valentina Ponti, Paola Sabbadini, Anna Amela Valsecchi, Massimo Di Maio, Amelie Anota

Blood (2025) 146 (Supplement 1): 4408.

https://doi.org/10.1182/blood-2025-4408

Published: 2025

Journal Articles

Determinants of renal survival in patients treated for monoclonal gammopathy of renal significance

Samuel Rubinstein, Yusha Liu, Rajshekhar Chakraborty, Michael Hughes, Suzanne Lentzsch, Jing Christine Ye, Divaya Bhutani

Blood (2025) 146 (Supplement 1): 3973.

https://doi.org/10.1182/blood-2025-3973

Published: 2025

Journal Articles

Lessons learned from the clinical trial portfolio of ixazomib in multiple myeloma: A systematic review and meta-analysis

Darshi Shah, Veer Shah, Karan Shah, Payton Utzman, Aaron Goodman, Rajshekhar Chakraborty, Ghulam Rehman Mohyuddin

Blood (2025) 146 (Supplement 1): 6199.

https://doi.org/10.1182/blood-2025-6199

Published: 2025

Journal Articles

Outcomes of patients with mayo stage IIIb systemic AL amyloidosis treated with daratumumab-based frontline therapy

Simon Zhen, Divaya Bhutani, Mathew Maurer, Karan Wats, Yevgeniy Brailovsky, Michael Hughes, Jai Radhakrishnan, Markus Mapara, Suzanne Lentzsch, Rajshekhar Chakraborty

Blood (2025) 146 (Supplement 1): 5740.

https://doi.org/10.1182/blood-2025-5740

Published: 2025

Journal Articles

Sustained remission following limited duration of bispecific antibody therapy in patients with relapsed/refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 5757.

https://doi.org/10.1182/blood-2025-5757

Published: 2025

Journal Articles

Machine learning uncovers prognostically distinct myeloma cast nephropathy phenotypes not captured by standard risk stratification systems

Michael Hughes, Yiran Peng, Shikun Wang, Andrew Laine, Jai Radhakrishnan, Metodi Balev, Divaya Bhutani, Markus Mapara, Andrew Eisenberger, Suzanne Lentzsch, Rajshekhar Chakraborty

Blood (2025) 146 (Supplement 1): 5756.

https://doi.org/10.1182/blood-2025-5756

Published: 2025

Journal Articles

An open-label multicenter Phase 1/2 trial of venetoclax-dexamethasone in Relapsed/Refractory t(11;14)-positive systemic AL amyloidosis

Rajshekhar Chakraborty, Anita D'Souza, Prashant Kapoor, Shikun Wang, Divaya Bhutani, Susan Bal, Keith Stockerl-Goldstein, Sherin Selvan, Othman Akhtar, Vaishali Sanchorawala, Suzanne Lentzsch

Blood (2025) 146 (Supplement 1): 694.

https://doi.org/10.1182/blood-2025-694

Published: 2025

Journal Articles

Long-term follow-up of venetoclax therapy in AL amyloidosis

Divaya Bhutani, Rajshekhar Chakraborty, Suzanne Lentzsch, Michael Hughes, Michaela Liedtke, Jeffrey Zonder, Mansen Yu, Anita D'Souza

Blood (2025) 146 (Supplement 1): 7497.

https://doi.org/10.1182/blood-2025-7497

Published: 2025

Journal Articles

Safety and efficacy of linvoseltamab as a simplified monotherapy first-line regimen in NDMM: Initial Results from the window of opportunity Phase 1/2 LINKER-MM4 trial

Blood (2025) 146 (Supplement 1): 697.

https://doi.org/10.1182/blood-2025-697

Published: 2025

Journal Articles

Phase 1/2 dose escalation and expansion study of etentamig in patients with relapsed or refractory light chain amyloidosis

Blood (2025) 146 (Supplement 1): 692.

https://doi.org/10.1182/blood-2025-692

Published: 2025

Journal Articles

Impact-AL: A phase 2 clinical trial of teclistamab and daratumumab in previously untreated AL amyloidosis

Rajshekhar Chakraborty, Anita D'Souza, Omar Siddiqi, Shikun Wang, Margaret Doyle, Sanjay Vara, Benjamin Schroeder, Jordan Schecter, Catherine Higgins, Renee Smith, Vaishali Sanchorawala, Suzanne Lentzsch

Blood (2025) 146 (Supplement 1): 2197.

https://doi.org/10.1182/blood-2025-2197

Published: 2025

Journal Articles

Better renal response with daratumumab in patients with monoclonal immunoglobulin deposition disease

Divaya Bhutani, Samuel Rubinstein, Rajshekhar Chakraborty, Michael Hughes, Suzanne Lentzsch, Lu Dai, Micah Richardson, J Christine Ye

Blood (2025) 146 (Supplement 1): 2194.

https://doi.org/10.1182/blood-2025-2194

Published: 2025

Journal Articles

Computational dissection of immune reconstitution across diverse conditioning regimens in adults with sickle cell disease undergoing allogeneic stem cell transplantation

Abdul-Hamid Bazarbachi, HuiHui Ma, Simon Zhen, Miriam Klahr, Diane M. George, Christian Gordillo, Samuel Pan, Amer Assal, Andrew Eisenberger, David Diuguid, Ran Reshef, Suzanne Lentzsch, Divaya Bhutani, Rajshekhar Chakraborty, Monica Bhatia, Markus Mapara

Blood (2025) 146 (Supplement 1): 4255.

https://doi.org/10.1182/blood-2025-4255

Published: 2025

Journal Articles

Safety and efficacy of elranatamab in patients with relapsed and/or refractory immunoglobulin light-chain amyloidosis

Pedro Vianna, Rajshekhar Chakraborty, Shahrier Hossain, Divaya Bhutani, Shannon Miller, Annemarie Rossi, Sarah A. M. Cuddy, Rodney H. Falk, Suzanne Lentzsch, Jacob P. Laubach, Giada Bianchi

Blood (2025) 146 (16): 1929–1935.

https://doi.org/10.1182/blood.2025028383

Published: 2025

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Effect of isatuximab use in combination with autologous stem cell transplant on mobilized stem cell product and post-transplant immune recovery - Results of a randomized prospective Phase 2 trial

Systematic review of non-icans neurological toxicities associated with BCMA and GPRC5D-directed CAR-T cell therapy in plasma cell dyscrasia

Deciphering the IKZF1 and MAP4K2 protein interactome in RASMut multiple myeloma reveals a novel regulatory pathway of IKZF1

Interim analysis of LimiTec, a prospective trial of limited-duration teclistamab for relapsed/refractory multiple myeloma

Isatuximab for the treatment of monoclonal gammopathy of renal significance (MGRS): Results from a prospective multicenter Phase 2 trial

A machine learning model to predict risk of infection in patients receiving bispecific antibody therapy for multiple myeloma

Quality and timing of patient-reported outcome reports in randomized controlled trials (RCTs) of patients with lymphoid malignancies: Analysis of 83 RCTs published between 2015 and 2025

Determinants of renal survival in patients treated for monoclonal gammopathy of renal significance

Lessons learned from the clinical trial portfolio of ixazomib in multiple myeloma: A systematic review and meta-analysis

Outcomes of patients with mayo stage IIIb systemic AL amyloidosis treated with daratumumab-based frontline therapy

Sustained remission following limited duration of bispecific antibody therapy in patients with relapsed/refractory multiple myeloma

Machine learning uncovers prognostically distinct myeloma cast nephropathy phenotypes not captured by standard risk stratification systems

An open-label multicenter Phase 1/2 trial of venetoclax-dexamethasone in Relapsed/Refractory t(11;14)-positive systemic AL amyloidosis

Long-term follow-up of venetoclax therapy in AL amyloidosis

Safety and efficacy of linvoseltamab as a simplified monotherapy first-line regimen in NDMM: Initial Results from the window of opportunity Phase 1/2 LINKER-MM4 trial

Phase 1/2 dose escalation and expansion study of etentamig in patients with relapsed or refractory light chain amyloidosis

Impact-AL: A phase 2 clinical trial of teclistamab and daratumumab in previously untreated AL amyloidosis

Better renal response with daratumumab in patients with monoclonal immunoglobulin deposition disease

Computational dissection of immune reconstitution across diverse conditioning regimens in adults with sickle cell disease undergoing allogeneic stem cell transplantation

Safety and efficacy of elranatamab in patients with relapsed and/or refractory immunoglobulin light-chain amyloidosis

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only